He was referred to a supra-regional cancer management centre where he received three cycles of baby-BOP (low-dose bleomycin, vincristine, and cisplatin) with significant tumour marker response (AFP 2081 and normal LDH two weeks after commencing treatment). This low-dose regimen was preferred over conventional BEP (bleomycin, etoposide, cisplatin) to minimise toxicity, in particular, the risk of infection and bleeding as at the time of treatment commencement the scrotal mass was deeply ulcerated. The gene discussed is AFP; the disease is neoplasm.